64 related articles for article (PubMed ID: 19959088)
1. Pharmacologic monitoring and determinants of intracytoplasmic drug levels.
Mahon FX
Best Pract Res Clin Haematol; 2009 Sep; 22(3):381-6. PubMed ID: 19959088
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
Forrest DL; Trainor S; Brinkman RR; Barnett MJ; Hogge DE; Nevill TJ; Shepherd JD; Nantel SH; Toze CL; Sutherland HJ; Song KW; Lavoie JC; Power MM; Abou-Mourad Y; Smith CA
Leuk Res; 2009 Feb; 33(2):271-5. PubMed ID: 18762338
[TBL] [Abstract][Full Text] [Related]
3. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Mahon FX; Molimard M
Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
[No Abstract] [Full Text] [Related]
4. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
6. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
8. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Carella AM; Lerma E
Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in chronic myeloid leukaemia.
Hernández-Boluda JC; Cervantes F
Best Pract Res Clin Haematol; 2009 Sep; 22(3):343-53. PubMed ID: 19959085
[TBL] [Abstract][Full Text] [Related]
12. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine.
Ross DM
Intern Med J; 2009 Oct; 39(10):708. PubMed ID: 19849764
[No Abstract] [Full Text] [Related]
14. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.
Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K
Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML.
Larson RA
Clin Adv Hematol Oncol; 2009 Feb; 7(2):S3-5. PubMed ID: 19391309
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
20. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times.
Wang Y; Chia YL; Nedelman J; Schran H; Mahon FX; Molimard M
Ther Drug Monit; 2009 Oct; 31(5):579-84. PubMed ID: 19730279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
